RxDoctor Payments Data

Eileen Gilman

Family · Chesapeake, VANPI 1063681864

Payments from drug & device makers

$6,372in general payments, 2019–2025

Across 292 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Corcept Therapeutics$857
  • Amgen$408
  • Novo Nordisk$403
  • Radius Health, Inc.$370
  • Sanofi-aventis U.S. LLC$339
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,372100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,372 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide94$161,306
OzempicSemaglutide55$106,636
FarxigaDapagliflozin Propanediol105$90,632
JardianceEmpagliflozin62$87,772
Humulin R U-500 KwikpenInsulin Regular, Human35$40,837
JanuviaSitagliptin Phosphate36$39,610
TrulicityDulaglutide15$24,338
Humulin R U-500Insulin Regular, Human15$23,922
HumalogInsulin Lispro36$19,636
Tresiba Flextouch U-100Insulin Degludec23$16,187
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$15,686
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp68$14,987
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$14,647
InvokanaCanagliflozin18$14,643
Humalog Kwikpen U-100Insulin Lispro44$14,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi$1,006$210,177158 claims
Novo NordiskOzempic, Novolog$403$112,61189 claims
Boehringer IngelheimJardiance, Tradjenta$103$94,45175 claims
AstraZenecaFarxiga$60$90,632105 claims
MerckJanuvia$25$39,61036 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$90$3,536278 claims
AbbVieSynthroid$330$1,14428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →